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Volume 59, Number 5 Letters to the Editor 1475the incidence of patients who experience asymptomatic troponin
elevations.
With respect to the particular levels of troponin that were
considered signiﬁcant in our study, this point deserves further clar-
iﬁcation. An acknowledged limitation of the Vascular Study Group
of New England (VSGNE) database is that speciﬁc levels of
troponin are not collected. Similarly, details relating to the assays
used and the upper reference limits used at the various institutions
that contribute data to the VSGNE are not captured. We agree
with Dr Sandoval and Dr Garcia that this information, if it had
been available, would potentially be useful in further understanding
the association between postoperative troponin elevation and long-
term survival. We believe that further study using precise troponin
value measurements that would allow for troponin threshold ana-
lyses and stratiﬁcation by relevant cut points is warranted.
Results of the Coronary Artery Revascularization Prophylaxis
(CARP)2 trial inﬂuence not only our practice but also our deci-
sion not to draw any conclusions in our study that would contra-
dict its ﬁndings. We do not suggest prophylactic coronary
revascularization as a ﬁrst-line approach to decrease postoperative
myocardial ischemia. Further studies, such as the currently
enrolling Coronary CT Angiography Vascular Events in Non-
cardiac Vascular Surgery Patients Cohort Evaluation (CTA-
VISION)3 trial, are better suited than ours to shed light on
whether there are “high-risk” anatomies that might beneﬁt
from coronary revascularization. Instead, we recommend periop-
erative medical optimization as a potential intervention, where
evidence-based guidelines are more clearly established.4
We are in complete agreement with Drs Sandoval and Garcia
that increased awareness of new consensus recommendations5 for
routine postoperative troponin testing in high-risk patients is
needed. Our ﬁnding that isolated troponin elevations after
vascular surgery are associated with reduced postoperative 5-year
survival suggests that these events deserve to be taken seriously.
Future study will more clearly reveal whether routine postopera-
tive troponin testing is a cost-effective way in which to improve
long-term clinical outcomes after vascular surgery.
Jessica P. Simons, MD, MPH
Andres Schanzer, MD
Division of Vascular and Endovascular Surgery
University of Massachusetts Medical School
Worcester, Mass
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http://dx.doi.org/10.1016/j.jvs.2014.01.004Regarding “Discontinuation of preoperative
clopidogrel is unnecessary in peripheral arterial
surgery”
We read with interest the recent article by Saadeh and Sfeir1
reporting the safety of maintaining perioperative clopidogrel in
patients undergoing peripheral arterial surgery. This supplements
similar ﬁndings from our report from the Vascular Study Group
of New England (VSGNE) demonstrating that patients can safely
undergo peripheral arterial operations while taking clopidogrel
without increased incidence of serious bleeding complications,
including bleeding requiring reoperation or increased transfusion
requirement.2
Interestingly, there is persistent variation in practice surround-
ing perioperative clopidogrel management among vascular sur-
geons. Hamish et al3 reported that 43% and 55% of surgeons
would preferentially stop clopidogrel before carotid endarterec-
tomy (CEA) for symptomatic patients and asymptomatic patients,
respectively. Furthermore, these authors noted that more than 49%
of surgeons would stop clopidogrel more than 7 days before sur-
gery, irrespective of symptom status. One can infer that these
biases reﬂect the ongoing presumption that clopidogrel is associ-
ated with increased serious bleeding complications at the time of
surgery. We also determined in another VSGNE-based study of
more than 4500 patients, which demonstrated that protamine
reduced bleeding complications after CEA, that there was no evi-
dence that clopidogrel was associated with major adverse bleeding
complications.4 Reoperation for bleeding after CEA occurred in
1.0% of patients taking clopidogrel versus 1.2% in patients not tak-
ing clopidogrel (P ¼ .67). Of note, almost all patients were
receiving antiplatelet therapy at the time of surgery (73% aspirin
only, 3% clopidogrel only, 13% aspirin and clopidogrel). Accord-
ingly, we strongly support Saadeh’s and Sfeir’s conclusion that clo-
pidogrel can be safely maintained perioperatively, which is
especially important for patients with strong indications for its
use, such as those with drug-eluting coronary stents or symptom-
atic carotid disease.
David H. Stone, MD
Brian W. Nolan, MD, MS
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Reply
Considering that dual antiplatelet therapy with aspirin and clo-
pidogrel now is so commonly prescribed to atherosclerotic pa-
tients, vascular surgeons worldwide are still facing the issue of
the optimal perioperative treatment of these patients on a regular
JOURNAL OF VASCULAR SURGERY
1476 Letters to the Editor May 2014basis. On the basis of a large prospective study of patients under-
going major vascular procedures, we showed that maintaining clo-
pidogrel up to the time of surgery is not associated with increased
bleeding complications or transfusion requirements. Therefore, we
believe that vascular surgeons must become familiar with proce-
dures performed in patients receiving clopidogrel and teach their
residents how to minimize the risk of bleeding in such patients.
We also thank Stone and colleagues for their support of our
conclusion.
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Regarding “Comparison of outcomes following
endovascular repair of abdominal aortic aneurysms
based on size threshold”
Keith and colleagues1 report a comparison of outcomes after
endovascular repair in small (4.0-4.9 cm) vs larger abdominal
aortic aneurysm (AAA). Endovascular repair was performed in
157 patients with small AAA, of whom 15.3% had complications.
Four randomized trials, two of open repair and two of endovascu-
lar repair,2 have demonstrated that there is no beneﬁt from repair
of AAA smaller than 5.5 cm, making this one of the best-proven
tenets of AAA management. The authors state that they have
continued to perform these procedures because of their previous
experience of low perioperative morbidity and mortality. Surely,
this is not sufﬁcient justiﬁcation; would reports of low morbidity
and mortality after appendectomy in healthy patients lead them
to recommend that procedure for all?
A second justiﬁcation for repair of small AAA offered by Keith
and colleagues, that the repair threshold should be lowered
because many patients with a smaller AAA will eventually cross
it, is fallacious.3 After lowering the repair threshold from the 5.5
cm established by randomized trials to, for example, 5.0 cm, it
could then be argued that many patients with a diameter of 4.5
cm will reach this new threshold in a few years; therefore we
must now lower it to 4.5 cm, and so on, until we get to 3.0 cm
or lower, in a clear reductio ad absurdum. The key point is that
many patients will not cross the 5.5 cm threshold and will never
need repair.
Their third justiﬁcation is their concern that if repair is de-
ferred, the patient might no longer be eligible for endovascular
repair and then might need open repair, as occurred in the
CAESAR trial. However, given that this “harm” did not inﬂuence
the results of either endovascular small aneurysm trial and that
another of the best-proven tenets of AAA management is that
endovascular repair offers no long-term advantage over open
repair,4 this justiﬁcation also fails.
Their implied fourth justiﬁcation, that patients with small
AAA fared better after endovascular repair than did patients with
large AAA, is no justiﬁcation at alldthose who do not need a
treatment often fare better with it than those who do need treat-
ment. If the concern is that patients would have had worse out-
comes if repaired later, this is precisely what the four
randomized trials disproved.Accepting the authors’ statement that after excluding rup-
tures, a ﬁfth of the small AAA were symptomatic (which is surpris-
ing because none of the 567 patients with small AAA followed for
up to 8 years in the ADAM study5 had nonerupture-related symp-
toms), what valid justiﬁcation remains for repairing the other 80%?
What did the authors say to the 15% who suffered complications
after a procedure that they may have never needed? Performing
endovascular repair on small AAA causes harm and does not confer
any beneﬁt, at least not to the patient.
Frank A. Lederle, MD
Center for Chronic Disease Outcomes Research
VA Health Care System (111-O)
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It is of no surprise that the article by Keith et al1 has stirred up
some strong opinions regarding size threshold and abdominal
aortic aneurysm (AAA) repair, and we appreciate the opportunity
to respond. While the comments made in the Letter to the Editor
by Dr Lederle are the standard argument made against endovascu-
lar AAA repair (EVAR) for small AAAs, the problem is that they
represent a static perspective focusing solely on a rigid AAA size
threshold of 5.5 cm established on the basis of randomized evi-
dence from clinical trials comparing open repair versus surveil-
lance.2,3 However, with these studies predating and not
including endovascular options, this threshold should not simply
be extrapolated to EVAR. There is ample evidence comparing
open AAA repair with EVAR to suggest lower overall risk with a
different distribution of fewer severe complications favoring
EVAR over open repair.4,5 Although long-term survival curves
merge a few years after repair, there is still early survival advantage
favoring EVAR, which extends long-term for younger patients.6
Additionally, another study from our institution demonstrated
the early advantage of EVAR over open repair that is sustained
over 9 years.7 Therefore, the need for a different risk-to-beneﬁt
crossover point for EVAR on the basis of size threshold is readily
supported, especially in patients with a greater life expectancy. In
the more recently published randomized trials comparing EVAR
and surveillance for small AAAs, both PIVOTAL and CAESAR
showed equivalence in terms of rupture risk and mortality, with
a signiﬁcant number of patients in the surveillance group eventu-
ally requiring EVAR.8,9 The underlying implication here is that
there is a subgroup of patients with small AAAs who underwent
EVAR that is driving equivalence in both of these trials, and this
